We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program
News

Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program

Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program
News

Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affomix to Provide Antibodies for Kalgene’s Therapeutic and Companion Diagnostics Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Affomix Corporation has announced that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer.

Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics. The company's portfolio of oncology products is at various stages in development, from assay development to advanced clinical trials.

“After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets”

Under the terms of the agreement Affomix will generate antibodies against several proprietary targets selected by Kalgene. Affomix will utilize its Y2HExpress™ technology for the selection of single-chain antibodies with substantially increased throughput, and specificity, over conventional Y2H and alternative antibody selection methodologies.

Financial terms of the service agreement were not disclosed, nor were the financial milestones related to diagnostic and therapeutic applications.

“After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets”, said Dr. T. Nathan Yoganathan, President and CEO of Kalgene Pharmaceuticals Inc. “Y2HExpress™ has the ability to select antibodies at an unprecedented level of specificity, combined with very favorable financial advantages,” Yoganathan continued.

“The application of Affomix technology will accelerate our product development schedule”, said Robert Davidson, Director of Science and Technology for Kalgene.
Advertisement